{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-064791","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.289994+00:00","generated_at":"2026-06-04T23:40:17.350823+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ACAD's Phase 3 ADVANCE-2 trial of pimavanserin misses primary endpoint in negative symptoms of schizophrenia","bullets":["Pimavanserin failed Phase 3 ADVANCE-2 trial for negative symptoms of schizophrenia; primary endpoint not met.","Safety and tolerability consistent with prior trials, showing low adverse event rate.","No financial or regulatory guidance provided in this 8-K; further analysis may follow."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-064791","json":"https://secwatch.observer/filing/0001193125-24-064791.json","markdown":"https://secwatch.observer/filing/0001193125-24-064791.md","text":"https://secwatch.observer/filing/0001193125-24-064791.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000119312524064791/0001193125-24-064791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000119312524064791/d786050d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:40:17.350823+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}